πŸ‡ΊπŸ‡Έ FDA
Patent

US 11236339

Modulation of GYS1 expression

granted A61KA61K31/7088A61K45/06

Quick answer

US patent 11236339 (Modulation of GYS1 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/7088, A61K45/06, A61P, A61P25/28